Less than a week after reporting disappointing third quarter earnings, Aegerion Pharmaceuticals Inc. cheered the Street by disclosing an agreement with Astrazeneca plc to acquire the approved orphan drug Myalept (metreleptin for injection) for $325 million up front, with no milestones or royalties attached.